| Renal Cell Carcinoma
Lenvima vs Welireg
Side-by-side clinical, coverage, and cost comparison for renal cell carcinoma.Deep comparison between: Lenvima vs Welireg with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsWelireg has a higher rate of injection site reactions vs Lenvima based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Welireg but not Lenvima, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Lenvima
Welireg
At A Glance
Oral
Once daily
Multi-kinase inhibitor
Oral
Once daily
HIF-2α inhibitor
Indications
- Differentiated Thyroid Gland Carcinoma
- Renal Cell Carcinoma
- Liver carcinoma
- Endometrial Carcinoma
- Von Hippel-Lindau Syndrome
- Renal Cell Carcinoma
- Pheochromocytoma
- Paraganglioma
Dosing
Differentiated Thyroid Gland Carcinoma 24 mg orally once daily until disease progression or unacceptable toxicity.
Renal Cell Carcinoma (first-line, with pembrolizumab) 20 mg orally once daily in combination with pembrolizumab 200 mg IV infusion over 30 minutes every 3 weeks until disease progression or unacceptable toxicity or up to 2 years.
Renal Cell Carcinoma (previously treated, with everolimus) 18 mg orally once daily in combination with everolimus 5 mg orally once daily until disease progression or unacceptable toxicity.
Liver carcinoma 12 mg orally once daily for patients >=60 kg or 8 mg orally once daily for patients <60 kg, until disease progression or unacceptable toxicity.
Endometrial Carcinoma 20 mg orally once daily in combination with pembrolizumab 200 mg IV infusion over 30 minutes every 3 weeks until unacceptable toxicity or disease progression.
Von Hippel-Lindau Syndrome Adults: 120 mg orally once daily. Pediatric patients >=12 years: 120 mg orally once daily if >=40 kg or 80 mg orally once daily if <40 kg.
Renal Cell Carcinoma Adults: 120 mg orally once daily.
Pheochromocytoma Adults: 120 mg orally once daily. Pediatric patients >=12 years: 120 mg orally once daily if >=40 kg or 80 mg orally once daily if <40 kg.
Paraganglioma Adults: 120 mg orally once daily. Pediatric patients >=12 years: 120 mg orally once daily if >=40 kg or 80 mg orally once daily if <40 kg.
Contraindications
—
—
Adverse Reactions
Most common (>=20%) Hypertension, fatigue, diarrhea, arthralgia/myalgia, decreased appetite, decreased weight, nausea, stomatitis, headache, vomiting, proteinuria, palmar-plantar erythrodysesthesia syndrome, abdominal pain, dysphonia, hypothyroidism, hemorrhagic events, rash, musculoskeletal pain.
Serious Hepatic encephalopathy, hepatic failure, cardio-respiratory arrest, sepsis, myocardial infarction, pneumonitis, acute kidney injury, renal failure, dehydration, thrombocytopenia, dyspnea, anemia.
Postmarketing Pancreatitis, impaired wound healing, cholecystitis, nephrotic syndrome, arterial aneurysms/dissections/rupture.
Most common (>=25%) Decreased hemoglobin, fatigue, increased creatinine, headache, dizziness, increased glucose, nausea, musculoskeletal pain, decreased lymphocytes, increased alanine aminotransferase, decreased sodium, increased potassium, increased aspartate aminotransferase, anemia, dyspnea, increased calcium, decreased leukocytes, increased alkaline phosphatase.
Serious Anemia, hypoxia, hemorrhage, pneumonia, pleural effusion, pyelonephritis, hypertension, retinal detachment, central retinal vein occlusion, anaphylaxis reaction.
Postmarketing Not reported in label.
Pharmacology
Lenvatinib is a multi-kinase inhibitor that inhibits VEGFR1, VEGFR2, and VEGFR3 kinase activities as well as FGFR1-4, PDGFRA, KIT, and RET, suppressing pathogenic angiogenesis and tumor growth; in combination with pembrolizumab or everolimus, it demonstrates enhanced antiangiogenic and antitumor activity.
Belzutifan is a hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor that binds to HIF-2α and blocks its interaction with HIF-1β, leading to reduced transcription of HIF-2α target genes associated with cellular proliferation, angiogenesis, and tumor growth.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Lenvima
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (11/12)
Welireg
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Lenvima
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (0/8) · Qty limit (4/8)
Welireg
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (2/8)
Humana
Lenvima
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (2/3)
Welireg
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Lenvima.
$5/fillfill
Welireg Co-Pay Coupon Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
LenvimaView full Lenvima profile
WeliregView full Welireg profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.